ASM International press release ( ASMIY ): Q4 Revenue of €698M (-13.7% Y/Y). Adjusted net earnings of €170M. More on ASM International Seeking Alpha’s Quant Rating on ASM International Historical earnings data for ASM International Dividend scorecard for ASM International Financial information for ASM International
ASM International press release ( ASMIY ): Q4 Revenue of €698M (-13.7% Y/Y). Adjusted net earnings of €170M. More on ASM International Seeking Alpha’s Quant Rating on ASM International Historical earnings data for ASM International Dividend scorecard for ASM International Financial information for ASM International
Key Points VR Advisory Services Ltd initiated a new position in Telephone and Data Systems (TDS), adding 573,005 shares for an estimated $23.49 million based on quarterly average prices. The quarter-end value of the stake increased by $23.49 million due entirely to new share purchases. This transaction accounts for 3.7% of the fund’s reportable U.S. equity assets under management (AUM). Post-filin...
Key Points VR Advisory Services Ltd initiated a new position in Telephone and Data Systems (TDS), adding 573,005 shares for an estimated $23.49 million based on quarterly average prices. The quarter-end value of the stake increased by $23.49 million due entirely to new share purchases. This transaction accounts for 3.7% of the fund’s reportable U.S. equity assets under management (AUM). Post-filing, the fund holds 573,005 shares valued at $23.49 million. This position represents 3.7% of VR Advisory Services Ltd’s U.S. equity AUM, placing it outside the fund’s top five holdings. 10 stocks we like better than Telephone And Data Systems › What happened According to a February 17, 2026, SEC filing, VR Advisory Services Ltd established a new position in Telephone and Data Systems (NYSE:TDS), acquiring 573,005 shares. The estimated transaction value was $23.49 million, calculated using the average share price over the quarter. The reported stake’s value at quarter-end also totaled $23.49 million, in line with share purchases and price appreciation. What else to know This new position amounts to 4.5% of the fund’s reportable U.S. equity assets under management as of December 31, 2025. Top holdings after the filing: NYSE: YPF: $116.85 million (19% of AUM) NYSE: AERO: $109.73 million (17% of AUM) NASDAQ: KSPI: $84.17 million (13% of AUM) NYSE: IRS: $44.16 million (7% of AUM) NASDAQ: HEPS: $40.85 million (6.5% of AUM) As of February 17, 2026, shares of Telephone and Data Systems were priced at $46.54, up 16.0% over the past year, outperforming the S&P 500 Index by 6.45 percentage points. Company Overview Metric Value Revenue (TTM) $1.23 billion Net Income (TTM) ($75.46 million) Dividend Yield 0.34% Price (as of market close 2/17/26) $46.54 Company Snapshot Telephone and Data Systems, Inc. offers wireless solutions, IoT services, broadband, cloud-based television, and traditional telecommunications products through UScellular and TDS Telecom segments. It generates revenue prim...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Enovix Corp (Symbol: ENVX) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $5.05 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 43.4. A bullish investor could look at ENVX's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ENVX shares: Looking at the chart above, ENVX's low point in its 52 week range is $4.6112 per share, with $16.49 as the 52 week high point — that compares with a last trade of $5.07. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
oonal Moderna ( MRNA ) is up ~10% in after-hours trading Tuesday after settling patent litigation with A rbutus Biopharma ( ABUS ) and Genevant Sciences ( ROIV ). Moderna will pay $950M in Q3 with no future royalties owed. The charge will be incurred in Q1. As a result, the company now expects cash and cash equivalents at the end of the year of $4.5B-$5B. However, Moderna could potentially be on t...
oonal Moderna ( MRNA ) is up ~10% in after-hours trading Tuesday after settling patent litigation with A rbutus Biopharma ( ABUS ) and Genevant Sciences ( ROIV ). Moderna will pay $950M in Q3 with no future royalties owed. The charge will be incurred in Q1. As a result, the company now expects cash and cash equivalents at the end of the year of $4.5B-$5B. However, Moderna could potentially be on the hook for more money. The biotech will appeal to the US Federal Circuit that its government-contractor immunity defense limits its liability under a federal statute. If Moderna wins, it will not owe anything else. If the court finds that Moderna is liable, it will pay up to an additional $1.3B within 90 days of the decision. The settlement covers litigation related to Moderna's Spikevax and mRESVIA vaccines "and provides certainty going forward for Moderna's full infectious disease portfolio, including mNEXSPIKE , mCOMBRIAX, and its future vaccine pipeline, with no future royalties owed," according to a company news release . In February, a federal judge in Delaware said that the dispute should be settled by a jury trial. More on Moderna Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation EMA recommends authorization of Moderna combination COVID/flu vaccine CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
"There was never really a point at which insurance alone would have prevented ships from going through the Strait of Hormuz," he said, adding "Just because you've got a naval escort doesn't mean to say you're safe."
"There was never really a point at which insurance alone would have prevented ships from going through the Strait of Hormuz," he said, adding "Just because you've got a naval escort doesn't mean to say you're safe."
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.8 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this drug developer would post earnings of $0.93 pe...
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.8 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this drug developer would post earnings of $0.93 per share when it actually produced earnings of $1.46, delivering a surprise of +56.99%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Rigel, which belongs to the Zacks Medical - Drugs industry, posted revenues of $69.8 million for the quarter ended December 2025, in line with the Zacks Consensus Estimate. This compares to year-ago revenues of $57.6 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Rigel shares have lost about 19.2% since the beginning of the year versus the S&P 500's gain of 0.5%. What's Next for Rigel? While Rigel has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings r...
Staar Surgical (STAA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.67%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0...
Staar Surgical (STAA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.67%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0.21 per share when it actually produced earnings of $0.37, delivering a surprise of 76.19%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Staar Surgical , which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $64.04 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 0.50%. This compares to year-ago revenues of $59 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Staar Surgical shares have added about 44.7% since the beginning of the year versus the S&P 500's gain of 6.2%. What's Next for Staar Surgical? While Staar Surgical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of...
Ross Stores (ROST) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.50%. A quarter ago, it was expected that this discount retailer would post earnings of $0.81 per share ...
Ross Stores (ROST) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.50%. A quarter ago, it was expected that this discount retailer would post earnings of $0.81 per share when it actually produced earnings of $1, delivering a surprise of 23.46%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Ross Stores , which belongs to the Zacks Retail - Discount Stores industry, posted revenues of $5.21 billion for the quarter ended January 2023, surpassing the Zacks Consensus Estimate by 1.65%. This compares to year-ago revenues of $5.02 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Ross Stores shares have lost about 4.4% since the beginning of the year versus the S&P 500's gain of 3.7%. What's Next for Ross Stores? While Ross Stores has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions....
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Loma Negra Compania Industrial Argentina Sociedad Anonima (Symbol: LOMA) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $9.815 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 43.4. A bullish investor could look at LOMA's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of LOMA shares: Looking at the chart above, LOMA's low point in its 52 week range is $7.04 per share, with $14.17 as the 52 week high point — that compares with a last trade of $9.90. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Pregnant migrant girls are being sent to a Texas shelter flagged as medically risky toggle caption Patricia Lim/KUT News The Trump administration is sending all pregnant unaccompanied minors apprehended by immigration enforcement to a single group shelter in South Texas. The decision was made over urgent objections from some of the administration's own health and child welfare officials, who say b...
Pregnant migrant girls are being sent to a Texas shelter flagged as medically risky toggle caption Patricia Lim/KUT News The Trump administration is sending all pregnant unaccompanied minors apprehended by immigration enforcement to a single group shelter in South Texas. The decision was made over urgent objections from some of the administration's own health and child welfare officials, who say both the facility and the region lack the specialized care the girls need. That's according to seven officials who work at the Office of Refugee Resettlement within the U.S. Department of Health and Human Services, which takes custody of children who cross the border without a parent or legal guardian, or are separated from family by immigration authorities. The children remain in ORR's care until they can be released to an adult or deported, or turn 18. Sponsor Message All of the officials asked not to be named for fear of retaliation. Since late July, more than a dozen pregnant minors have been placed at the Texas facility, which is in the small border city of San Benito. Some were as young as 13, and at least half of those taken in so far became pregnant as a result of rape, the officials said. Their pregnancies are considered high risk by definition, particularly for the youngest girls. "This group of kids is clearly recognized as our most vulnerable," one of the officials said. Rank-and-file staff, the official said, are "losing sleep over it, wondering if kids are going to be placed in programs where they're not going to have access to the care they need." The move marks a sharp departure from longstanding federal practice, which placed pregnant, unaccompanied migrant children in ORR shelters or foster homes around the country that are equipped to handle high-risk pregnancies. The ORR officials said they were never told why the girls are being concentrated in a single location, let alone in this particular shelter in Texas. But they — along with more than a dozen forme...
Leigh-Ann Russell, BNY CIO and Global Head of Engineering, discusses upskilling employees with AI, internal AI platform. She speaks with Bloomberg’s Tim Stenovec and Carol Massar from the Bloomberg Invest conference in New York City. (Source: Bloomberg)
Leigh-Ann Russell, BNY CIO and Global Head of Engineering, discusses upskilling employees with AI, internal AI platform. She speaks with Bloomberg’s Tim Stenovec and Carol Massar from the Bloomberg Invest conference in New York City. (Source: Bloomberg)